Atara Biotherapeutics, Inc. (ATRA) Just Reaches 52-Week High?

January 15, 2018 - By Michael Collier

Investors sentiment increased to 1.54 in Q3 2017. Its up 0.26, from 1.28 in 2017Q2. It increased, as 8 investors sold Atara Biotherapeutics, Inc. shares while 16 reduced holdings. 9 funds opened positions while 28 raised stakes. 26.16 million shares or 3.51% more from 25.27 million shares in 2017Q2 were reported.
Invesco Ltd has 18,791 shares. Alps Advsr Inc stated it has 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Rhumbline Advisers has 31,598 shares for 0% of their portfolio. Neuberger Berman Group Incorporated Lc has 0.02% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 1.12M shares. Eagle Asset Mngmt accumulated 1.49M shares or 0.15% of the stock. Essex Management Company Ltd Llc holds 0.06% or 25,905 shares. Swiss National Bank & Trust invested in 28,600 shares or 0% of the stock. 8,553 are held by Sg Americas Securities Limited Co. Perceptive Advsr Limited Co reported 35,106 shares stake. Moreover, Bridger Limited Liability Com has 1.64% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 1.65M shares. Credit Suisse Ag has 25,582 shares. Blackrock holds 1.99M shares or 0% of its portfolio. Dimensional Fund Advsr Lp holds 0% or 22,771 shares. Vanguard Grp Incorporated holds 0% or 918,150 shares in its portfolio. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Mngmt reported 39,330 shares.

Since August 10, 2017, it had 0 insider buys, and 16 selling transactions for $2.51 million activity. Haqq Christopher sold 7,604 shares worth $112,159. $16,931 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by Gallagher Carol Giltner on Tuesday, August 15. MCGRATH JOHN also sold $60,102 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares. 3,021 shares were sold by Clark Mitchall G., worth $43,291 on Tuesday, August 15. Soffer Gad had sold 9,464 shares worth $140,802.

The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) hit a new 52-week high and has $29.66 target or 5.00 % above today’s $28.25 share price. The 8 months bullish chart indicates low risk for the $864.33M company. The 1-year high was reported on Jan, 15 by Barchart.com. If the $29.66 price target is reached, the company will be worth $43.22M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 27.54% or $6.1 during the last trading session, reaching $28.25. About 3.69M shares traded or 708.01% up from the average. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 7.28% since January 15, 2017 and is downtrending. It has underperformed by 23.98% the S&P500.

Analysts await Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to report earnings on March, 8. They expect $-1.14 EPS, down 80.95 % or $0.51 from last year’s $-0.63 per share. After $-1.02 actual EPS reported by Atara Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.76 % negative EPS growth.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Ratings Coverage

Among 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Atara Biotherapeutics had 18 analyst reports since September 9, 2015 according to SRatingsIntel. On Thursday, August 31 the stock rating was maintained by Jefferies with “Buy”. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) earned “Sell” rating by Citigroup on Tuesday, December 15. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The firm earned “Neutral” rating on Wednesday, January 3 by Citigroup. On Friday, October 9 the stock rating was initiated by William Blair with “Outperform”. The stock has “Mkt Perform” rating by JMP Securities on Friday, September 25. The firm has “Buy” rating given on Monday, October 24 by Jefferies. Citigroup maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Monday, August 22 with “Sell” rating. The stock has “Buy” rating by Jefferies on Thursday, June 22. JMP Securities maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rating on Tuesday, December 15. JMP Securities has “Market Outperform” rating and $40 target.

More notable recent Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news were published by: Fool.com which released: “Why SandRidge Energy, Atara Biotherapeutics, and Hovnanian Enterprises Jumped …” on December 29, 2017, also Seekingalpha.com with their article: “Atara Biotherapeutics: What The FDA Clearance For ATA-188 Phase 1 Study At US …” published on January 12, 2018, Globenewswire.com published: “Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at US …” on January 10, 2018. More interesting news about Atara Biotherapeutics, Inc. (NASDAQ:ATRA) were released by: Seekingalpha.com and their article: “Atara Biotherapeutics: What The FDA Acceptance Of The Two Phase 3 Trials …” published on January 01, 2018 as well as Fool.com‘s news article titled: “Why Atara Biotherapeutics Stock Is Bolting Higher Today” with publication date: December 29, 2017.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $864.33 million. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.